An observational study in Non-small Cell Lung Cancer, NSCLC and NSCLC, Stage III, sponsored by MSD Italia S.r.l.. Recruiting at 25 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-14.
Sponsored by MSD Italia S.r.l. (part of Merck & Co., Inc) · Observational
This is a non-interventional, retrospective observational study to improve knowledge regarding the diagnosis and treatments of patients who have/had non-small cell lung cancer (NSCLC), either early stage (stage I-II).
Due to heterogeneity of patients with stage I-III Non Small Cell Lung Cancer (NSCLC), there is not a unique common therapeutic approach and there is no consensus about the optimal timing, sequencing and combination of surgery, chemotherapy and radiotherapy across the spectrum of early stage and locally advance disease. Consequently, the choice of local treatment modality can vary across countries and centers.
6,641 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,665 are open to participants now.
This study's planned enrollment of 600 is above the median of 164 across 974 observational studies indexed under Carcinoma, Non-Small-Cell Lung.
Browse Carcinoma, Non-Small-Cell Lung studies →MSD Italia S.r.l. is the lead sponsor of 3 studies on the registry; 3 are open to participants now.
Counted across the registry records on this site, refreshed daily.
The study population will consist of patients with early stage and locally advanced NSCLC (stage I-III) who had completed curative treatment planning and subsequent at least 18-months follow-up between January 2018 and January 2021.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
NSCLC treatment approaches in Real-World practice
Percentage of patients undergoing to: 1. surgical resection of the lung cancer with curative intent; 2. definitive (chemo)radiotherapy (defined as any regimen of chemotherapy administered with concurrent radiotherapy) 3. neoadjuvant treatment (4 cycles) before surgery 4. adjuvant treatments (4 cycles) after surgery
Time frame: Restrospective data capture from January 2018 to January 2021.
Percentage of patients discusses in multidisciplinary team
Multidisciplinary team defined as the involvement of radiotherapy unit, pneumology and/or interventional pneumology unit in patient discussion.
Time frame: Restrospective data capture from January 2018 to January 2021
Healthcare resource utilization aof different therapeutic approaches
Healthcare resources used to manage the patients will be described in terms of lab tests and/or outpatient visits and/or drug therapy and/or diagnostic tests.
Time frame: Restrospective data capture from January 2018 to January 2021.
Direct medical costs of different therapeutic approaches
The cost of the therapeutic approach (cost of illness) will be estimated through an activity-based costing (ABC) technique which allows to calculate the full cost of a service by measuring the cost of each individual activity/resource related to it.
Time frame: Restrospective data capture from January 2018 to January 2021.
NSCLC treatments timeline in Real-World practice
Median Time from: 1. diagnosis/multidisciplinary referral to surgery or start of radioterapy 2. surgery/completion of Radiotherapy to satrt of adjiuvant treatmen
Time frame: Restrospective data capture from January 2018 to January 2021.
Biomarkers profile evaluation at NSCLC diagnosis
Percentage of PD-L1, EGFR/ALK, KRAS test performed along with results
Time frame: Restrospective data capture from January 2018 to January 2021.
PD-L1 Biomarker profile evaluation at NSCLC diagnosis
Percentage of PD-L1 test performed along with results
Time frame: Restrospective data capture from January 2018 to January 2021.
EGFR/ALK Biomarkers profile evaluation at NSCLC diagnosis
Percentage of EGFR/ALK test performed along with results
Time frame: Restrospective data capture from January 2018 to January 2021.
KRAS Biomarkers profile evaluation at NSCLC diagnosis
Percentage of KRAS test performed along with result
Time frame: Restrospective data capture from January 2018 to January 2021.
Plan to share: No
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Carcinoma, Non-Small-Cell Lung →